Abstract

BackgroundColistin has been used for therapy of carbapenem-resistant Gram-negative infections in Thailand, especially carbapenem-resistant A. baumannii and P. aeruginosa, for more than 10 years. However, the prevalence of colistin-resistant A. baumannii or P. aeruginosa is still less than 5%. Colistin-resistant Enterobacteriaceae has been increasingly reported globally over the past few years and the use of colistin in food animals might be associated with an emergence of colistin resistance in Enterobacteriaceae. This study aimed to determine the effect of colistin exposure in hospitalized patients who received colistin on development of colistin-resistant (CoR) Escherichia coli (EC) or Klebsiella pneumoniae (KP) colonization and infection.MethodsA prospective observational study was performed in adult hospitalized patients at Siriraj Hospital who received colistin for treatment of infections during December 2016 and November 2017. The surveillance culture samples were collected from the stool and the site of infection of each patient who received colistin at the study enrollment, days 3 and 7 after the study enrollment, and once a week thereafter for determination of CoR EC and CoR KP. CoR EC and CoR KP were also tested for a presence of mcr-1 gene.ResultsOne hundred thirty-nine patients were included. Overall prevalence of CoR EC or CoR KP colonization was 47.5% among 139 subjects. Prevalence of CoR EC or CoR KP colonization was 17.3% of subjects at study enrollment, and 30.2% after study enrollment. Use of fluoroquinolones, aminoglycosides, and colistin was found to be significantly associated with CoR EC or CoR KP colonization. The mcr-1 gene was detected in 13.0% of CoR EC or CoR KP isolates, and in 27.3% of subjects with CoR EC or CoR KP colonization. CoR EC or CoR KP colonization persisted in 65.2% of the subjects at the end of the study. Five patients with CoR KP infections received combination antibiotics and they were alive at hospital discharge.ConclusionsPrevalence of CoR EC or CoR KP colonization in hospitalized patients receiving colistin was high and it was associated with the use of colistin. Therefore, patients who receive colistin are at risk of developing CoR EC or CoR KP colonization and infection.

Highlights

  • Colistin has been used for therapy of carbapenem-resistant Gram-negative infections in Thailand, especially carbapenem-resistant A. baumannii and P. aeruginosa, for more than 10 years

  • Colistin therapy was given to 79.1% of subjects with documented bacterial infections, and in 77.1% of episodes of documented bacterial infection

  • Most of the colistin-resistant Enterobacteriaceae found at swine farms in Thailand was E. coli while the prevalence of CoR Escherichia coli (EC) isolates observed in Colonization after enrollment (n = 42) No Colonization after enrollment (n = 73) p-value

Read more

Summary

Introduction

Colistin has been used for therapy of carbapenem-resistant Gram-negative infections in Thailand, especially carbapenem-resistant A. baumannii and P. aeruginosa, for more than 10 years. The prior use of colistin in humans and animals is associated with colistin resistance and/or increased colistin minimal inhibitory concentration (MIC) in Gram-negative bacteria [3,4,5]. The emergence of a plasmid-mediated gene (mcr-1) that encodes a protein conferring resistance to colistin in Enterobacteriaceae isolated from foods, animals, and patients was reported from China in 2015 [7]. Association between colistin use for therapy of carbapenem-resistant A. baumannii and P. aeruginosa infections in humans and the emergence of colistin-resistance in these bacteria has been reported [9,10,11,12,13]. The prevalence of and association between colistin use for therapy of carbapenem-resistant Gram-negative bacterial infections in humans and the emergence of colistin resistance in Enterobacteriaceae in individuals who receive colistin are not well-understood

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call